fashion -WSS

fashion

author：fashion 2025-08-31 21:00:03 - browse：8

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

WSS

Global cancer cases to surge 77% by 2050, WHO report says

Maisha Meds is a PBM, but don't call it that

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Dana Farber says 6 studies to be retracted and 31 corrected

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

hotspot

fashion

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Medicare bonuses could stop drug shortages under Senate plan

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

After affirmative action ruling, medical educators look to 'holistic review'

Future doctors need a strong humanities education

Malaria cases in Florida and Texas: Here’s what you need to know

Cardiologists urge adding sexual orientation, gender identity to health records

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Global cancer cases to surge 77% by 2050, WHO report says

focus

To bolster infectious disease surveillance, genomics powerhouses team up

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

TikTok, Instagram influencers need more rules for drug ads

AstraZeneca stays mum on Medicare drug pricing negotiations

Future doctors need a strong humanities education

A single Democrat is willing to weaken Medicare negotiation power

focus

leisure time

focus

entertainment